Latest Hospitality News

EMVision Medical Devices is set to activate its sixth and final pivotal trial site at UCLA Health, advancing its emu™ brain scanner towards FDA submission. Meanwhile, the Continuous Innovation Study grows with the addition of Box Hill Hospital.

Tyro Payments Limited reported FY25 results with strong top-line growth and margin expansion, setting a confident outlook for FY26 backed by AI-driven efficiency and an expanded market.

Tyro Payments delivered solid FY25 results with a 10.6% rise in EBITDA and accelerated growth initiatives, including expansion into new $40 billion addressable markets and a pilot banking platform.

Tyro Payments reported modest transaction growth and a 10.6% rise in EBITDA for FY25, while preparing for a CEO change and expanding into new industry verticals.

Imricor Medical Systems reports significant regulatory approvals and clinical trial progress, positioning itself as a disruptive force in the growing electrophysiology market. With a strengthened commercial pipeline and solid cash reserves, the company is poised for a pivotal growth phase.

Embelton Limited reports a notable decline in revenue and profit for FY2025 amid a challenging construction market, yet maintains its dividend payout, signaling cautious optimism.

Polynovo Limited reported a robust 23.3% increase in total revenue for FY25, driven by strong commercial sales growth across the US and international markets. The company is advancing its FDA PMA submission and expanding its global footprint amid strategic product development.

EVT Group has released an extensive valuation update on its diversified $2.3 billion property portfolio, spotlighting landmark Sydney CBD assets alongside a broad hospitality and entertainment footprint across Australia, New Zealand, and Germany.

Regal Partners Limited reported robust half-year results for 1H25, with funds under management reaching $17.7 billion and normalised net profit after tax hitting $44.8 million. The firm achieved record net inflows and maintained a strong balance sheet, signaling continued growth momentum.

EVT Group reported a 6.3% rise in normalised EBITDA to $160.8 million for FY25, led by record Hotels performance and resilient Entertainment results despite film supply challenges. The company declared a fully franked final dividend of 22 cents per share.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

EVT Limited reported solid full-year FY25 results with revenue and profit growth, driven by record hotel performance and a recovering entertainment division. The group signals confidence with a strong dividend and optimistic FY26 outlook.